{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:19:49Z","timestamp":1792703989511,"version":"4.5.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>While biologic therapies targeting type 2 (T2) inflammation reduce acute exacerbation rates in children with asthma and T2 inflammation, exacerbations still occur, and the underlying molecular mechanisms are poorly defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To identify multiple distinct molecular mechanisms implicated in asthma exacerbations by characterizing respiratory illnesses among urban children with eosinophilic asthma enrolled in a clinical trial comparing treatment with mepolizumab vs placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This is a secondary analysis of the Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (MUPPITS-2) double-blind, placebo-controlled, parallel-group, randomized clinical trial comparing treatment with mepolizumab vs placebo among children with exacerbation-prone asthma in low-income urban centers in 9 US cities. Data analysis was performed from September 2022 to April 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were randomized to receive either mepolizumab (aged 6-11 years: 40 mg; aged 12-17 years: 100 mg) or matching placebo by subcutaneous injection once every 4 weeks for 52 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary measurement was a transcriptomic modular analysis by RNA sequencing of nasal samples obtained during acute respiratory illnesses. Associations among upper airway transcriptional signatures, the clinical outcome of respiratory illnesses, and pulmonary functions were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 290 participants enrolled in the MUPPITS-2 trial, 108 participants (median [IQR] age, 10.0 [9.0-13.0] years; 48 [44%] female) were sampled during 176 acute respiratory illness events. During illness events resulting in asthma exacerbations, children receiving mepolizumab demonstrated decreased expression of an eosinophil-associated module associated with T2 inflammation (log<jats:sub>2<\/jats:sub> fold change [FC] estimate, \u22120.60; false discovery rate [FDR]\u2009&amp;amp;lt;\u2009.05) but increased expression of gene modules associated with epithelial and macrophage inflammatory pathways relative to children receiving placebo (log<jats:sub>2<\/jats:sub> FC estimates, 0.22-0.85; FDR\u2009&amp;amp;lt;\u2009.05). Both groups showed higher expression of mucus secretion and cellular stress response pathways during exacerbations relative to nonexacerbation illnesses. The mepolizumab group demonstrated upregulation of epithelial inflammatory pathways in exacerbations irrespective of a respiratory virus, while macrophage pathways contributed specifically to viral exacerbations. Three distinct, semiorthogonal inflammatory axes were shown to underlie the majority of the heterogeneity among exacerbations in the 2 groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The study\u2019s findings implicate multiple alternative inflammatory pathways associated with the epithelium and macrophages, as well as mucus hypersecretion, as mechanisms of residual acute exacerbations in children receiving mepolizumab. Further, they indicate that multiple distinct inflammatory axes can independently contribute to asthma exacerbations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03292588\">NCT03292588<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2025.2044","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:00:42Z","timestamp":1752505242000},"page":"957","source":"Crossref","is-referenced-by-count":17,"title":["Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children"],"prefix":"10.1001","volume":"179","author":[{"given":"Matthew C.","family":"Altman","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Janczyk","sequence":"additional","affiliation":[{"name":"Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Doni","family":"Jayavelu","sequence":"additional","affiliation":[{"name":"Center for Systems Immunology, Benaroya Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Calatroni","sequence":"additional","affiliation":[{"name":"Rho Inc, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stokes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjit K.","family":"Khurana Hershey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sherenian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel G.","family":"Robison","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Gruchalla","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Zoratti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Teach","sequence":"additional","affiliation":[{"name":"Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan V.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Dill-McFarland","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice M.","family":"Becker","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkis","family":"Togias","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Gern","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Monroe Carell Jr Children\u2019s Hospital at Vanderbilt, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Inner City Asthma Consortium and Childhood Asthma in Urban Settings Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"40","key":"poi250031r1","doi-asserted-by":"publisher","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids.","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"poi250031r2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma.","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"poi250031r3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches.","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"poi250031r4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma.","volume":"16","author":"Lambrecht","year":"2015","journal-title":"Nat Immunol"},{"issue":"2","key":"poi250031r5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma.","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"9842","key":"poi250031r6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"poi250031r7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"poi250031r8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"poi250031r9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"poi250031r10","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u00df2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"poi250031r11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"poi250031r12","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma.","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"poi250031r13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.793409","article-title":"Biologics in asthma: a molecular perspective to precision medicine.","volume":"12","author":"Salter","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"poi250031r14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/all.14514","article-title":"Asthma exacerbations on benralizumab are largely non-eosinophilic.","volume":"76","author":"Poznanski","year":"2021","journal-title":"Allergy"},{"issue":"10","key":"poi250031r15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10351","key":"poi250031r16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"poi250031r17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41590-019-0347-8","article-title":"Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children.","volume":"20","author":"Altman","year":"2019","journal-title":"Nat Immunol"},{"issue":"6","key":"poi250031r18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jaci.2021.04.035","article-title":"Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children.","volume":"148","author":"Altman","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"poi250031r19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jaci.2022.01.020","article-title":"Seasonal airway microbiome and transcriptome interactions promote childhood asthma exacerbations.","volume":"150","author":"McCauley","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"poi250031r20","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2542-5196(22)00302-3","article-title":"Associations between outdoor air pollutants and non-viral asthma exacerbations and airway inflammatory responses in children and adolescents living in urban areas in the USA: a retrospective secondary analysis.","volume":"7","author":"Altman","year":"2023","journal-title":"Lancet Planet Health"},{"issue":"5","key":"poi250031r21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/bioinformatics\/btad279","article-title":"Kimma: flexible linear mixed effects modeling with kinship covariance for RNA-seq data.","volume":"39","author":"Dill-McFarland","year":"2023","journal-title":"Bioinformatics"},{"issue":"11","key":"poi250031r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: an R package for 'omics feature selection and multiple data integration.","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"poi250031r23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial.","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"poi250031r24","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma.","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"poi250031r25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"poi250031r26","doi-asserted-by":"publisher","first-page":"7310","DOI":"10.4049\/jimmunol.178.11.7310","article-title":"Inhibition of allergen-induced airway remodeling in Smad 3-deficient mice.","volume":"178","author":"Le","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"poi250031r27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1165\/rcmb.2016-0307TR","article-title":"Transforming growth factor \u00df1 function in airway remodeling and hyperresponsiveness: the missing link?","volume":"56","author":"Ojiaku","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"poi250031r28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2213-2600(19)30055-4","article-title":"Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies.","volume":"7","author":"Pividori","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"poi250031r29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaci.2016.10.041","article-title":"Epigenome-wide analysis links SMAD3 methylation at birth to asthma in children of asthmatic mothers.","volume":"140","author":"DeVries","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"poi250031r30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1183\/13993003.00196-2017","article-title":"Macrophage dysfunction in the pathogenesis and treatment of asthma.","volume":"50","author":"Fricker","year":"2017","journal-title":"Eur Respir J"},{"issue":"4","key":"poi250031r31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.202206-1183OC","article-title":"Autoantibody-mediated macrophage dysfunction in patients with severe asthma with airway infections.","volume":"207","author":"Son","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"poi250031r32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1164\/rccm.201803-0461OC","article-title":"Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL): a placebo-controlled, double-blind study.","volume":"199","author":"Sabogal Pi\u00f1eros","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"poi250031r33","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/02770903.2022.2136526","article-title":"Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.","volume":"60","author":"Menigoz","year":"2023","journal-title":"J Asthma"},{"issue":"5","key":"poi250031r34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma.","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"poi250031r35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma.","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"issue":"4","key":"poi250031r36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"poi250031r37","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaci.2013.11.025","article-title":"Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease.","volume":"133","author":"Poole","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"poi250031r38","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaci.2020.02.018","article-title":"Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.","volume":"145","author":"Kicic","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2836335\/jamapediatrics_altman_2025_oi_250031_1755882482.63012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:01:16Z","timestamp":1756825276000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2836335"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2025.2044","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}